Commonwealth Equity Services LLC trimmed its position in GE HealthCare Technologies by 34.4% during the third quarter, selling 91,088 shares and reducing its holding to 173,486 shares valued at approximately $13.03 million. This divestiture contributed to a broader reshuffling among large investors: Mirae Asset Global Investments increased its stake by 4.2% to 159,882 shares, Wedge Capital Management initiated a new position worth about $26.86 million, and National Bank of Canada FI more than doubled its holding to 899,693 shares. Institutional and hedge funds collectively control 82.06% of GE HealthCare’s outstanding shares, underscoring the company’s heavy reliance on large-scale investors for liquidity and market support.

In its latest quarterly report, GE HealthCare posted adjusted earnings per share of $1.07, exceeding the consensus estimate of $1.05, while generating revenue of $5.14 billion compared to the expected $5.07 billion. The quarter’s 5.8% year-over-year revenue growth was accompanied by a net margin of 10.94% and a return on equity of 22.52%. Management issued full-year guidance for fiscal 2025 earnings per share in the range of $4.510 to $4.630, indicating confidence in continued top-line resilience and margin expansion driven by its diagnostic imaging and service offerings.

GE HealthCare’s board approved a quarterly dividend of $0.035 per share, representing an annualized payout of $0.14 and a dividend payout ratio of 2.89%. This return of capital complements the company’s growth investments in software analytics and lifecycle services. On the sell-side, 14 analysts currently cover the stock, evenly split between Buy and Hold recommendations. Investors can gauge sentiment shifts through these ratings, which reflect expectations for GE HealthCare to balance disciplined capital allocation with continued technological innovation.